Short answer
Olema Pharmaceuticals, Inc. (OLMA) filed its fiscal 2025 10-K annual report with the SEC on Mar 16, 2026.
- Top risk flagged: FDA regulatory risk: reliance on successful OPERA-01 Phase 3 trial results expected fall 2026 for NDA submission and potential FDA approval by late 2027
FY2025 key financial metrics · XBRL
- Net income
- −$162M
- −25.5% YoY
- EPS (diluted)
- −$1.87
- +15.0% YoY
- ROE
- -33.9%
- −2.3 pp YoY
- Operating cash flow
- −$147M
- −40.6% YoY
Source: XBRL data from the Olema Pharmaceuticals, Inc. (OLMA) FY2025 10-K on SEC EDGAR. USD.
Olema Pharmaceuticals, Inc. FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Clinical-stage biopharma developing next-generation targeted therapies for ER+ breast cancer, emphasizing oral small molecule endocrine therapies
- New emphasis: Initiated pivotal Phase 3 OPERA-01 trial for palazestrant monotherapy (2023) and Phase 3 OPERA-02 trial with ribociclib combination (2025)
- Strategic shift: Collaboration with Novartis for ribociclib supply, advancing palazestrant as potential endocrine therapy of choice in frontline metastatic breast cancer
- Quantitative highlight: Over 400 patients treated with palazestrant; FDA Fast Track designation granted in July 2022
- Noteworthy: Second product OP-3136 entered clinical development in late 2024 targeting KAT6, with IND clearance and ongoing Phase 1 trial enrollment
Management Discussion & Analysis
- Revenue and profitability details not disclosed in the provided MD&A excerpt
- Cash flow, capital allocation, buybacks, dividends, and capex information not included
- Forward-looking statements indicating potential risks and uncertainties affecting actual results and events timing
Risk Factors
- FDA regulatory risk: reliance on successful OPERA-01 Phase 3 trial results expected fall 2026 for NDA submission and potential FDA approval by late 2027
- Geopolitical/macroeconomic threat: funding and operational risks tied to global economic uncertainty and volatile credit markets impacting capital raises and collaborations
- Supply chain vulnerability: dependence on third-party contract manufacturers (CMOs) for clinical and potential commercial production with no in-house manufacturing
- Competitive risk: Novartis collaboration supplying ribociclib for OPERA-02 trial, with palazestrant competing against established CDK4/6 inhibitors like palbociclib and ribociclib
- Financial risk: accumulated deficit $597.6 million with net losses increasing to $162.5 million in 2025, requiring ongoing substantial capital raises including $237 million net from 2024 private placement
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.